Case Conversations in the Diagnosis and Management of Polyneuropathies: Focus on CIDP and MMN

---

ONLINECMECNEComplimentary - No Fee

Monday, April 24, 2023, 1:32 PM - Friday, June 28, 2024, 2:32 PM

The overall goal of this curriculum is for learners to be better able to recognize CIDP and MMN in a timely manner and use appropriate therapies for the management of both. Each of these interactive 25-minute presentations will conclude with 5 minutes of faculty Q&A and be accompanied by 20 to 40 synchronized slides.

This program is supported by an independent educational grant from Takeda Pharmaceuticals USA, Inc. and has been developed through a strategic partnership between:
The Perelman School of Medicine at Penn; MedScape Education; Infusion Access Foundation; National Infusion Center Association.

Click on the Online Content & Test button to be redirected to MedScape's website and the online content.

Bringing CIDP to Life: Merging Science, Symptoms, and Diagnosis
This activity is intended for neurologists, nurse practitioners, physician assistants, nurses, infusion specialists, and other clinicians who see/treat patients with immune-mediated neuropathies (eg, primary care physicians, orthopedists/orthopedic surgeons, pharmacists). 

The goal of this activity is for learners to be better aware of the causes, symptoms, and diagnosis of CIDP. 

Multifocal Motor Neuropathy: Getting Into Focus with Causes, Symptoms, and Diagnosis
This activity is intended for neurologists, nurse practitioners (NPs), physician assistants (PAs), nurses, infusion specialists, and other clinicians who see/treat patients with immune-mediated neuropathies (eg, primary care physicians [PCPs], orthopedists/orthopedic surgeons, pharmacists).

The goal of this activity is for learners to be better aware of the causes, symptoms, and diagnosis of multifocal motor neuropathy (MMN).

Therapeutic Considerations for the Management of CIDP and MMN: Case Reviews
This activity is intended for neurologists, nurse practitioners, physician assistants, nurses, infusion specialists, and other clinicians who see/treat patients with immune-mediated neuropathies (eg, primary care physicians, orthopedists/orthopedic surgeons, pharmacists).

The goal of this activity is for learners to be better able to recognize best practices in the management of CIDP and MMN.

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Designation of Credit
Physicians: Penn Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This program provides 1.50 NCPD hours

AMA PRA Category 1 Credits™ (1.50 hours), Non-Physician Attendance / Participation (1.50 hours), NCPD Hours (ANCC) (1.50 hours)

Mitigation of Relevant Financial Relationships

Penn Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

No faculty are available for this activity at this time.